novo news - Search News

Novo Nordisk faces US Senate committee

CNBC on MSN · 17m

Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices

Novo Nordisk's top executive is slated to face a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard Jørgensen,

Reuters on MSN · 1h

Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing

U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,

Investopedia on MSN · 17h

Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices

Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.

Novo Nordisk, Denmark

Novo Nordisk is bigger than Denmark's economy — but the prime minister isn't worried about another Nokia

Denmark Prime Minister Mette Frederiksen downplayed concerns that Ozempic maker Novo Nordisk (NVO), the Scandinavian nation’s largest corporation, could someday drag down its economy the way the once-dominant Nokia (NOK) did to Finland in the 2000s.

Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’

But Danish prime minister Mette Frederiksen isn't worried about a 'Nokia risk' from pharma giant.

EconoTimes · 18h

Denmark’s PM Downplays Concerns Over Novo Nordisk’s Dominance Amid Economic Growth Surge

Denmarks Prime Minister, Mette Frederiksen, rejected concerns over the economic risks posed by Novo Nordisks rapid growth. Despite comparisons to Finlands past dependence on Nokia, Frederiksen highlighted Denmarks

1h

Hitting the Pharmaceutical Jackpot With Novo’s Ozempic and Wegovy

Hi, it’s Bob in New York. I’ve been writing about drug costs for years, and Ozempic and Wegovy turn out to be in a unique ...

1d

Ozempic and Wegovy Sales Will Soon Pay for $68 Billion of Novo R&D

Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...

3don MSN

Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

15h

Novo CEO Blames Ozempic’s High Cost on Drug Middlemen’s Tactics

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...

3don MSN

Novo’s Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next.

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

3don MSN

Novo Nordisk shares drop nearly 5% on disappointing obesity pill data

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

FierceBiotech3d

Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results